#USA #Sunnyvale #Oxford Nanopore #Cepheid #GeneXpert

Cepheid and Oxford Nanopore Expand Their Collaboration

In a noteworthy advancement for molecular diagnostics, Cepheid, a renowned Danaher company specialized in infectious disease diagnostics, alongside Oxford Nanopore Technologies, a pioneer in nanopore-based genomic analysis, has announced an expansion of their collaboration. This development comes on the heels of a successful initial partnership phase that was unveiled at the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global 2025. The companies will now focus on improving workflows aimed at the rapid identification of bacterial and fungal pathogens.

Overview of the Expanded Collaboration

The second phase of this partnership aims to enhance the capabilities previously developed. The new workflows will facilitate not only the identification of pathogens but also antimicrobial resistance profiling and genomic antibiotic susceptibility testing predictions specifically for research into bloodstream infections and sepsis. Utilizing both culture isolates and positive blood cultures, this upgraded workflow represents a collaborative effort to make advanced infectious disease research both practical and accessible.

Vitor Rocha, President of Cepheid, expressed the intention behind this collaboration: "Phase two reflects our shared commitment to making advanced infectious disease research more practical and widely achievable." By harnessing the strengths of Cepheid’s GeneXpert® platform alongside Oxford Nanopore's sequencing technology, the partnership aims to broaden access to vital infectious disease information. The innovative designs promise ease of use and increased efficiency.

Successful Phase One Review

The initial workflow developed under the partnership has been a subject of interest among infectious disease researchers. Designed to analyze bacterial and fungal pathogens for bloodstream infections, this workflow was made available to multiple researchers in a beta format. Encouragingly, the feedback has been highly positive, indicating a promising future for the project. By the third quarter of 2026, the workflow is expected to transition into an early access program for select scientist leaders in the field.

Dr. Rahul Batra, Deputy Director at the Centre for Clinical Infection Diagnostics Research (CIDR) at Guy's and St Thomas' NHS Foundation Trust, emphasized the importance of rapid genomic testing in the improvement of patient care. By enabling timely and accurate predictions of antibiotic resistance, the ongoing collaboration has the potential to significantly enhance public health surveillance regarding emerging infectious strains.

Future Aspirations and Developments

The long-term vision of both Cepheid and Oxford Nanopore is to deliver a comprehensive in vitro diagnostic (IVD) solution specifically for complex infectious diseases, facilitating timely and accurate clinical decision-making. At the ongoing ESCMID Global event, both companies will showcase their research progress and engage with the broader scientific community, marking a significant step forward in infectious disease diagnostics.

This partnership also serves as a reminder of the critical role that technology plays in modern medicine. As Cepheid and Oxford Nanopore continue to innovate, we can anticipate a future where rapid, accurate genomic insights are accessible at pivotal moments of clinical need.

In conclusion, the collaboration between Cepheid and Oxford Nanopore stands as a beacon for advancements in infectious disease research, reinforcing the importance of partnership in driving innovation.